22 patents currently held
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jun 2036. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jun 2036
Next term end
18
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Mar 2041 · High confidence
Also notable
Ends Jun 2036 · High confidence
Also notable
Ends Jan 2039 · High confidence
DLL3 Targeting Chimeric Antigen Receptors and Binding Agents
US 11,673,953
Cited by 8 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2041.
Inhibitory Chimeric Antigen Receptors
US 11,072,644
The most cited patent in this portfolio, cited by 13 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2036.
Modified CASPASE-9 Polypeptides and Methods of Use Thereof
US 11,326,156
Granted 2022. Computed term ends 2039.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 13, 2026The maintenance fee for DLL3 Targeting Chimeric Antigen Receptors and Binding Agents (US 11,673,953) comes due Dec 13, 2026. Unpaid by Jun 14, 2027, it lapses early.
- 1 fee due Feb 22, 2027The maintenance fee for Antibodies Against 4G7-DERIVED Chimeric Antigen Receptors (US 11,732,041) comes due Feb 22, 2027. Unpaid by Aug 23, 2027, it lapses early.
- 2 fees due Apr 10 to 17, 2027 · next Apr 10
- 1 fee due Aug 13, 2027The maintenance fee for Polynucleotides Encoding Rituximab-Resistant Chimeric Antigen Receptors (US 11,896,617) comes due Aug 13, 2027. Unpaid by Feb 14, 2028, it lapses early.
Recent changes
- Oct 28Assignment recorded on 1 record: Shenoy, Tanu R. to Allogene Therapeutics, Inc. Recorded Oct 28, 2026, executed Oct 8, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76541, frame 941.
- 1 of the patents on this record was granted since Aug 18, 2026
What they patent
The 5 largest of its 18 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Modified CASPASE-9 Polypeptides and Methods of Use Thereof | 3 in force | to Jun 2039 |
| Polynucleotides Encoding Rituximab-Resistant Chimeric Antigen Receptors | 2 in force | to Dec 2041 |
| DLL3 Targeting Chimeric Antigen Receptors and Binding Agents | 2 in force | to Mar 2041 |
| Fasl Expression and Fasr Gene Knockout to Protect Therapeutic Cells from Allogeneic Rejection and Activation-Induced Cell Death | 1 in force | to May 2044 |
| Protease-Activating CD45-GATE Car | 1 in force | to Oct 2043 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,072,644 | Inhibitory Chimeric Antigen Receptors In force · High confidence | In force | High confidence | |
| US 12,104,188 | Modified CASPASE-9 Polypeptides and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 11,326,156 | Modified CASPASE-9 Polypeptides and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 12,790,603 | Modified CASPASE-9 Polypeptides and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 12,447,178 | Method of Treatment Using ANTI-CD19 Rituximab-Resistant Chimeric Antigen Receptors In force · Medium confidence | In force | Medium confidence | |
| US 11,673,953 | DLL3 Targeting Chimeric Antigen Receptors and Binding Agents In force · High confidence | In force | High confidence | |
| US 12,606,623 | DLL3 Targeting Chimeric Antigen Receptors and Binding Agents held by Pfizer Inc. and Allogene Therapeutics, Inc. In force · High confidence | In force | High confidence | |
| US 12,163,169 | Inducible Chimeric Cytokine Receptors In force · High confidence | In force | High confidence | |
| US 11,786,553 | Chimeric Cytokine Receptors Bearing a PD-1 Ectodomain In force · High confidence | In force | High confidence | |
| US 12,528,856 | Chimeric Cytokine Receptors Comprising TGF Beta Binding Domains In force · High confidence | In force | High confidence |
Also on record, not counted in the 22: 2 patents in force now held by others · 37 applications pending · 9 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.